United States securities and exchange commission logo

                           October 25, 2023

       Ron Honig
       Chief Legal Officer
       EyePoint Pharmaceuticals, Inc.
       480 Pleasant Street
       Watertown, MA 02472

                                                        Re: EyePoint
Pharmaceuticals, Inc.
Statement on Form S-3
                                                            Filed October 20,
                                                            File No. 333-275125

       Dear Ron Honig:

              This is to advise you that we have not reviewed and will not
review your registration

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Jane
Park at 202-551-7439 with any questions.


                           Division of Corporation Finance

                           Office of Industrial Applications and

       cc:                                              Stephen Nicolai, Esq.